Alvine gobbles $21.5M to treat gastrointestinal disease | VentureBeat
DEALS.VENTUREBEAT.COM - Alvine Pharmaceuticals, developer of drugs for autoimmune and gastrointestinal diseases, has raised $21.5 million more in first-round funding, bringing the total to $47.5 million. The San Carlos, Calif. received the expansion from Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.
First tweeted by camillericketts.
From the Front Page
Socialsafe.net
- Comments
- Tweets (6)
Tweets
Sorry there have been no tweets in the last 7 days.
